Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19

By sjmartinez • October 10, 2022

Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs R, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ. Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19. Clin Infect Dis. 2022 Oct 10:ciac818. doi: 10.1093/cid/ciac818. Epub ahead of print. PMID: 36210483.

Tags: covid-19, Infectious Diseases, Publications, RNA, SARS-CoV-2, Symptom duration

The obstacle is the way: Finding a path to hepatitis C elimination

Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. The obstacle is the way: Finding a path to hepatitis C[...]

Severe Acute Respiratory Syndrome Coronavirus 2 Infection Alters Mediators of Lung Tissue Remodeling In Vitro and In Vivo

Wong M, Gain C, Sharma MB, Fotooh Abadi L, Hugo C, Vassilopoulos H, Daskou M, Fishbein GA, Kelesidis T. Severe Acute Respiratory Syndrome Coronavirus 2[...]

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]